ASH Annual Meeting and Exposition | Conference

The 2012 ASH Annual Meeting

December 11th 2012

Photos from the 54th American Society of Hematology (ASH) Annual Meeting and Exposition, held at the Georgia World Congress Center, Atlanta, GA, from December 8-11, 2012.

Ponatinib Stimulates 'Powerful' Response in Treatment-Resistant Leukemias

December 10th 2012

Researchers have demonstrated that ponatinib can overcome a wide range of mutations that cause treatment resistance-including the stubborn T315I mutation-in all stages of CML and Ph+ ALL.

Pomalidomide Labeled an Advance in Multiple Myeloma

December 10th 2012

The combination of pomalidomide and a steroid significantly improved outcomes for patients with MM who have exhausted other novel therapies, marking what researchers say is a notable advancement for a sizable proportion of those treated for the disease.

MLN9708 May be Alternative to Bortezomib in Multiple Myeloma

December 10th 2012

MLN9708 has shown comparable efficacy and greater convenience and tolerability than bortezomib, for patients with multiple myeloma.

Dr. Erba on Treatment-Related Mortality Rates in AML

December 9th 2012

Harry Erba, MD, PhD, professor of medicine and director, University of Alabama at Birmingham Hematologic Malignancy Program, explains the declining treatment-related mortality (TRM) rates in AML patients.

Dr. Barbui on Hematocrit Levels in Polycythemia Vera

December 9th 2012

Tiziano Barbui, MD, USC Hematology, Ospedali Riuniti di Bergamo, Bergamo, Italy, on hematocrit (HCT) levels in patients with polycythemia vera (PV).

Dr. Kumar on Managing Toxicities in the MLN9708 Study

December 9th 2012

Shaji K. Kumar, MD, Division of Hematology, Mayo Clinic, talks about managing toxicities in the MLN9708 study.

Ibrutinib Performance in CLL Patients Hailed

December 9th 2012

The novel targeted agent ibrutinib has demonstrated dramatic activity in hard-to-treat patients with CLL when used alone and in combination with rituximab.

Genes Predispose Some Anthracycline Patients to Heart Failure

December 9th 2012

Researchers have identified a genetic profile of the patients who are most likely to develop congestive heart failure after being treated with anthracyclines and then undergoing hematopoeitic stem cell transplant (HCT) for a range of blood cancers.

Dr. John Byrd Discusses Ibrutinib in CLL

December 8th 2012

John C. Byrd, MD, director of the division of hematology at The Ohio State University Comprehensive Cancer Center, discusses the new and updated results of a phase Ib/II study involving ibrutinib at the ASH Annual Meeting and Exposition.

Dr. Zelenetz Previews the 2012 ASH Annual Meeting

September 26th 2012

Andrew D. Zelenetz, MD, PhD, from Memorial Sloan-Kettering Cancer Center, previews several trials that will likely be presented at the 54th annual ASH meeting.

Dr. Mato on the Benefits of the JTCC Retrospective Trial

December 13th 2011

Dr. Anthony Mato From the John Theurer Cancer Center Discusses the Benefits of the JTCC Retrospective Trial

Photos From the 2011 ASH Annual Meeting and Exposition

December 13th 2011

A collection of photos from the ASH 53rd annual meeting at the San Diego Convention Center in San Diego, CA, from December 10-13, 2011.

Ponatinib Continues March to Potential Front-line Use in CML

December 13th 2011

PACE trial results show patients with previously treated CML achieved a 47% major cytogenetic response rate (MCyR) with ponatinib.

Final Analysis of VISTA Upholds Survival Benefit of Bortezomib at 5 Years: No Increase in Secondary Malignancies Found

December 13th 2011

The phase III VISTA trial upholds a persistent and statistically significant survival benefit for bortezomib in previously untreated multiple myeloma patients.

Novel CD20 Monoclonal Antibody Achieves Higher Response Rates Than Rituximab in Relapsed Non-Hodgkin Lymphoma

December 12th 2011

Treatment with GA101 (obinutuzumab) in patients with relapsed non-Hodgkin lymphoma (NHL) resulted in higher response rates compared with rituximab.

Dr. Anasetti Discusses the Trade-offs of BMT and PBSC

December 12th 2011

Dr. Claudio Anasetti from the H. Lee Moffitt Cancer Center Discusses the Trade-offs of BMT and PBSC

Novel Agent Targeting the B-Cell Receptor Shows Efficacy, Without Myelosuppression, in Chronic Lymphocytic Leukemia

December 12th 2011

First drug targeting Bruton's tyrosine kinase (Btk) produced high rates of remission in patients with CLL.

Chemotherapy Alone Increases Overall Survival for Early-stage Hodgkin Lymphoma

December 12th 2011

Twelve-year results from a Canadian Cancer Society Research Institute study shows chemotherapy alone increases survival in patients with Hodgkin Lymphoma.

Burden of Morbidity Reported for Long-term Survivors of Hematopoietic Cell Transplantation

December 12th 2011

Bone Marrow Transplant Survivor Study analysis suggests long-term survivors of HCT have high risk of chronic psychological, and physical health conditions